唤唤霸霸
2023-08-02
七喜
百济神州跌3.59% 股价跌破200美元大关
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":204627956699416,"tweetId":"204627956699416","gmtCreate":1690989427463,"gmtModify":1690989428760,"author":{"id":3547499860800538,"authorId":3547499860800538,"authorIdStr":"3547499860800538","name":"唤唤霸霸","avatar":"https://static.tigerbbs.com/4842950dc96000bc44fa266137eef860","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>七喜</p></body></html>","htmlText":"<html><head></head><body><p>七喜</p></body></html>","text":"七喜","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/204627956699416","repostId":2356343621,"repostType":2,"repost":{"id":"2356343621","pubTimestamp":1690986165,"share":"https://www.laohu8.com/m/news/2356343621?lang=&edition=full","pubTime":"2023-08-02 22:22","market":"hk","language":"zh","title":"百济神州跌3.59% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2356343621","media":"自选股智能写手","summary":"北京时间2023年08月02日22时22分,百济神州股票出现波动,股价大幅下挫3.59%。百济神州股票所在的生物技术行业中,整体跌幅为0.70%。该信息摘要如下:8月2日晚间,“创新药一哥”百济神州公布2023上半年业绩。半年报显示,百济神州营业收入较上年同期增加72.2%,达到72.51亿元,其中产品收入66.96亿元,同比增长82.2%,上半年的产品收入已接近2022全年的八成。归母净利润方面,百济神州上半年亏损52.19亿元,较去年同期的66.64亿元有所收窄。","content":"<html><body><article><p>北京时间2023年08月02日22时22分,<a href=\"https://laohu8.com/S/688235\">百济神州</a>(BGNE.us)股票出现波动,股价大幅下挫3.59%。截至发稿,该股报199.13美元/股,成交量12.2678万股,<span>换手率</span>0.12%,振幅7.93%。</p><p>最近的财报数据显示,该股实现<span>营业收入</span>4.48亿美元,<span>净利润</span>-3.48亿美元,<span>每股收益</span>-3.34美元,<span>毛利</span>3.47亿美元,市盈率-10.84倍。</p><p>机构评级方面,在所有26家参与评级的机构中,85%的券商给予买入建议,12%的券商给予持有建议,3%的券商给予卖出建议。</p><p><a href=\"https://laohu8.com/S/06160\">百济神州</a>股票所在的生物技术行业中,整体跌幅为0.70%。其相关个股中,<a href=\"https://laohu8.com/S/CLNN\">Clene Inc</a> C/Wts 30/12/2025 (To Pur Com)、Armata Pharmaceuticals Inc、Revelation Biosciences Inc C/Wts 10/01/2027 (To Pur Com)涨幅较大,<a href=\"https://laohu8.com/S/ALLR\">Allarity Therapeutics Inc</a>、Aptevo Therapeutics Inc、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为19.46%、18.45%、6.55%,振幅较大的相关个股有Eqrx Inc C/Wts 17/12/2026 (To Pur Com)、Pasithea Therapeutics Corp C/Wts 12/08/2026 (To Pur Com)、Armata Pharmaceuticals Inc,振幅分别为54.39%、28.24%、19.92%。</p><p>百济神州公司简介:百济神州有限公司是一家处于商业阶段的生物技术公司。主要从事分子靶向和免疫肿瘤药物的发现和开发。该公司已经开发了一个专有的癌症生物学平台,该平台解决了肿瘤-免疫系统相互作用的重要性,以及初级活检在开发新模型方面的价值。它已经开发了临床阶段的候选药物,抑制重要的肿瘤靶点布鲁顿酪氨酸激酶(BTK),RAF二聚体蛋白复合物和PARP蛋白家族,以及一种抑制免疫检查点蛋白受体PD-1的免疫肿瘤药物。它的地理部分是中国、美国和世界其他地区。</p><p>消息层面,截至22时22分,《<snpa>百济神州上半年净亏收窄至52亿,PD-1国内销售额增超四成</snpa>》资讯为影响百济神州的重要信息。该信息摘要如下:8月2日晚间,“创新药一哥”百济神州(BGNE.US;06160.HK;688235.SH)公布2023上半年业绩。半年报显示,百济神州营业收入较上年同期增加72.2%,达到72.51亿元,其中产品收入66.96亿元,同比增长82.2%,上半年的产品收入已接近2022全年的八成。归母净利润方面,百济神州上半年亏损52.19亿元,较去年同期的66.64亿元有所收窄。</p><p>(以上内容为自选股<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>机器写手Money Call完成,仅作为用户看盘参考,不作为交易依据。)</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州跌3.59% 股价跌破200美元大关</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州跌3.59% 股价跌破200美元大关\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-02 22:22 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308022222478473fb4b&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2023年08月02日22时22分,百济神州(BGNE.us)股票出现波动,股价大幅下挫3.59%。截至发稿,该股报199.13美元/股,成交量12.2678万股,换手率0.12%,振幅7.93%。最近的财报数据显示,该股实现营业收入4.48亿美元,净利润-3.48亿美元,每股收益-3.34美元,毛利3.47亿美元,市盈率-10.84倍。机构评级方面,在所有26家参与评级的机构中,85%的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308022222478473fb4b&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"688235":"百济神州","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","06160":"百济神州","BK1583":"高瓴概念","BK1500":"做空集合股","BGNE":"百济神州","BK1588":"回港中概股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308022222478473fb4b&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2356343621","content_text":"北京时间2023年08月02日22时22分,百济神州(BGNE.us)股票出现波动,股价大幅下挫3.59%。截至发稿,该股报199.13美元/股,成交量12.2678万股,换手率0.12%,振幅7.93%。最近的财报数据显示,该股实现营业收入4.48亿美元,净利润-3.48亿美元,每股收益-3.34美元,毛利3.47亿美元,市盈率-10.84倍。机构评级方面,在所有26家参与评级的机构中,85%的券商给予买入建议,12%的券商给予持有建议,3%的券商给予卖出建议。百济神州股票所在的生物技术行业中,整体跌幅为0.70%。其相关个股中,Clene Inc C/Wts 30/12/2025 (To Pur Com)、Armata Pharmaceuticals Inc、Revelation Biosciences Inc C/Wts 10/01/2027 (To Pur Com)涨幅较大,Allarity Therapeutics Inc、Aptevo Therapeutics Inc、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为19.46%、18.45%、6.55%,振幅较大的相关个股有Eqrx Inc C/Wts 17/12/2026 (To Pur Com)、Pasithea Therapeutics Corp C/Wts 12/08/2026 (To Pur Com)、Armata Pharmaceuticals Inc,振幅分别为54.39%、28.24%、19.92%。百济神州公司简介:百济神州有限公司是一家处于商业阶段的生物技术公司。主要从事分子靶向和免疫肿瘤药物的发现和开发。该公司已经开发了一个专有的癌症生物学平台,该平台解决了肿瘤-免疫系统相互作用的重要性,以及初级活检在开发新模型方面的价值。它已经开发了临床阶段的候选药物,抑制重要的肿瘤靶点布鲁顿酪氨酸激酶(BTK),RAF二聚体蛋白复合物和PARP蛋白家族,以及一种抑制免疫检查点蛋白受体PD-1的免疫肿瘤药物。它的地理部分是中国、美国和世界其他地区。消息层面,截至22时22分,《百济神州上半年净亏收窄至52亿,PD-1国内销售额增超四成》资讯为影响百济神州的重要信息。该信息摘要如下:8月2日晚间,“创新药一哥”百济神州(BGNE.US;06160.HK;688235.SH)公布2023上半年业绩。半年报显示,百济神州营业收入较上年同期增加72.2%,达到72.51亿元,其中产品收入66.96亿元,同比增长82.2%,上半年的产品收入已接近2022全年的八成。归母净利润方面,百济神州上半年亏损52.19亿元,较去年同期的66.64亿元有所收窄。(以上内容为自选股智能机器写手Money Call完成,仅作为用户看盘参考,不作为交易依据。)","news_type":1},"isVote":1,"tweetType":1,"viewCount":903,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/204627956699416"}
精彩评论